AUPH insider trading
NasdaqGM HealthcareAurinia Pharmaceuticals Inc.: insider trade history from SEC Form 4 filings.
About Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
Company website: www.auriniapharma.com
AUPH insider activity at a glance
FilingIQ tracks 228 insider transactions for AUPH in filings since Jan 29, 2021. The most recent transaction is dated Sep 10, 2026.
Across the full history, 43 open-market purchases
and 83 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on AUPH insider trades is 55.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest AUPH Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for AUPH?
- FilingIQ tracks 228 Form 4 insider transactions for AUPH (Aurinia Pharmaceuticals Inc.), covering filings from Jan 29, 2021 onwards. 2 of those are dated within the last 90 days.
- Are AUPH insiders net buyers or net sellers?
- Across the full Form 4 history for AUPH, 43 transactions (19%) were open-market purchases and 83 (36%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does AUPH insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is AUPH in?
- Aurinia Pharmaceuticals Inc. (AUPH) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $2.05B.
Methodology & sources
Every AUPH insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.